ASTAFEB 40

(Febuxostat 40 mg Tablet)

Structured in the same professional template as your previous products.

📘 ASTAFEB 40 TRAINING MANUAL

Advanced Uric Acid Control in CKD & Metabolic Patients

PRODUCT INTRODUCTION

Brand Name: ASTAFEB 40
Composition: Febuxostat 40 mg

Category: Xanthine Oxidase Inhibitor

TAGLINE & PUNCHLINE

Tagline:
👉Precision Uric Acid Control

Punchline:
👉Lower Uric. Protect the Kidney.

CLINICAL BACKGROUND

In CKD & Metabolic Syndrome patients:

• Hyperuricemia is common
• Uric acid contributes to:
  • Endothelial dysfunction
  • Hypertension
  • CKD progression
  • Gout attacks

Allopurinol limitations:

• Dose adjustment in CKD
• Hypersensitivity risk
• Variable uric acid control

👉 Febuxostat offers more consistent uric acid reduction.

MODE OF ACTION (MOA)

• Selective Xanthine Oxidase Inhibitor
• Blocks conversion of:
  • Hypoxanthine → Xanthine
  • Xanthine → Uric Acid

Clinical Effects:

✔ Reduces serum uric acid
✔ Prevents gout flares
✔ Supports renal protection
✔ Improves endothelial function

INDICATIONS

• Chronic hyperuricemia
• Gout
• CKD patients with high uric acid
• Diabetic nephropathy with hyperuricemia
• Hypertensive patients with elevated uric acid

DOSAGE

• 40 mg once daily
• Dose may be titrated as per physician
• Can be taken with or without food

FEATURE – ADVANTAGE – BENEFIT (FAB)

🔹 Feature

Selective xanthine oxidase inhibition

🔹 Advantage

Stronger uric acid reduction vs conventional therapy

🔹 Benefit

Better gout control & renal protection

USP

✔ More potent uric acid reduction
✔ Effective in CKD (mild–moderate)
✔ Once-daily dosing
✔ Lower hypersensitivity risk vs allopurinol

 SAFETY PROFILE

• Monitor liver function tests
• Initial gout flare possible
• Use cautiously in severe cardiovascular disease
• Dose adjustment based on renal status as per guidelines